Amgen Inc (NASDAQ:AMGN)

Tuesday’s trading has closed, but AMGN is being traded in the after-hours session. After-Hours quote »
144.09
Data as of 3:59pm ET
 +6.58 / +4.79%
Today’s Change
108.20
Today|||52-Week Range
145.49
+26.31%
Year-to-Date
Market Wrap: Existing Sales Outpace in Sept.; Loeb's Third Point Eyes Amgen; Daimler ...
6:10pm / Investing Channel
3 Stocks Dragging In The Drugs Industry
Oct 16 / TheStreet.com
Loeb urges Amgen to explore a break-up
5:56pm / FT.com
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo ...
Oct 15 / Zacks.com
Notable 52-Week Highs and Lows of the Day 10/21: (AKRX) (AMGN) (CCI) High; (OCN) (BBC...
4:42pm / Investing Channel
A Quick Look at Amgen, Inc.'s Drug Development Pipeline
Oct 15 / MotleyFool.com
Third Point's Notable Additions And Exit: Alibaba, eBay, Sony
4:38pm / Benzinga
'Fast Money' Recap: Now May Be the Time to Buy Energy Stocks
Oct 15 / TheStreet.com
One Reason eBay (EBAY) Stock Is Up Today
4:02pm / TheStreet.com
Can Dividend Stock GlaxoSmithKline plc Bounce Back?
Oct 14 / MotleyFool.com
Why Amgen (AMGN) Stock Is Rising in Afternoon Trading Today
3:21pm / TheStreet.com
Where Will Celgene Corporation Stock Be a Year From Now?
Oct 14 / MotleyFool.com
Amgen Sues Sanofi and Regeneron over PCSK9 Candidate - Analyst Blog
Oct 20 / Zacks.com
3 Dividend Stocks to Buy If the Market Crashes
Oct 14 / MotleyFool.com
Stocks To Watch For October 20, 2014
Oct 20 / Benzinga
Novartis Releases Data on Secukinumab for Plaque Psoriasis - Analyst Blog
Oct 13 / Zacks.com
Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors
Oct 17 / Benzinga
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog
Oct 13 / Zacks.com
Trade-Ideas: Amgen (AMGN) Is Today's "Barbarian At The Gate" Stock
Oct 17 / TheStreet.com
3 Companies With the Best Retirement Plans
Oct 12 / MotleyFool.com
Streetinsider.com's Hot Lunchtime Reads 10/17: (NFLX) (WLB) (GILD) (REGN)
Oct 17 / Investing Channel
Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery
Oct 10 / MotleyFool.com
Cramer: Regeneron's Head-to-Head Results 'Very Positive'
Oct 17 / TheStreet.com
Amgen Up on Positive Phase III Data on Psoriasis Biosimilar - Analyst Blog
Oct 09 / Zacks.com
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
Oct 17 / Benzinga
Amgen's Data on Evolocumab Published in The Lancet - Analyst Blog
Oct 08 / Zacks.com
AbbVie Inc to Shire: It's Not You, It's My Country
Oct 16 / MotleyFool.com
Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?
Oct 07 / MotleyFool.com

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.